Add this topic to your myFT Digest for news straight to your inbox
Plan by private equity-owned company raises hopes for European listings market
Chief executive points to strong prospects as skincare market expands
London-listed pharma group lifts sales and trumpets cost savings from Baxalta deal
Shares hardly move despite pharma group’s advances
Ornskov questions investors’ valuation of company after merger with Baxalta of US
Pandemic bonds, Flemming Ornskov, purls of wisdom
CEO Ornskov blames scepticism on investors’ ignorance of Baxalta, bought for $32bn
Drugmaker remains one of the fastest growing in its sector
Drugmaker shifts focus to integrating assets and launching new products
Takeover will help transform two midsized drugmakers into a leading force in rare diseases
UK pharma group to pay 37.5% premium over US target’s share price
Acquisition promises tax savings and a bigger slice of treatments for rare diseases and cancer
UK-listed drugmaker wants to offer cash without triggering bill
The UK-listed drug company has been looking for deals since its $30bn bid for Baxalta was rejected
Bid worth persevering with but chief says it will walk away if cause proves hopeless
Drugmaker holds back higher offer until US target opens its books
International Edition